IRMD

SEC source: 0000898432-21-000771 · form4.xml · derivative · entry 4

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,185 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000771 · form4.xml · derivative · entry 3

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,071

Underlying: Common Stock · 2,071 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000771 · form4.xml · nonDerivative · entry 2

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,058

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000771 · form4.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,021

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000770 · form4.xml · derivative · entry 8

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,463

Underlying: Common Stock · 2,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F8 · derivative.exercise_date: On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F8 · derivative.expiration_date: On December 7, 2020, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000770 · form4.xml · derivative · entry 7

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,575

Underlying: Common Stock · 1,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F7 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F7 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000770 · form4.xml · derivative · entry 6

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,143

Underlying: Common Stock · 4,143 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F4 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2021 through December 7, 2024.

F5 · derivative.exercise_date: If the relative measure at December 7, 2024 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting will be double the nominal granted shares.

F6 · derivative.exercise_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F4 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2021 through December 7, 2024.

F5 · derivative.expiration_date: If the relative measure at December 7, 2024 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting will be double the nominal granted shares.

F6 · derivative.expiration_date: Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

SEC source: 0000898432-21-000770 · form4.xml · derivative · entry 5

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,143

Underlying: Common Stock · 4,143 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2024. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000770 · form4.xml · nonDerivative · entry 4

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,996

SEC source: 0000898432-21-000770 · form4.xml · nonDerivative · entry 3

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,072

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000770 · form4.xml · nonDerivative · entry 2

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,340

SEC source: 0000898432-21-000770 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,960

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000757 · form4.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 856,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $44.00 to $45.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000898432-21-000756 · form4.xml · derivative · entry 3

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000756 · form4.xml · nonDerivative · entry 2

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,385

SEC source: 0000898432-21-000756 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000745 · form4.xml · derivative · entry 9

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,743

Underlying: Common Stock · 1,257 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 6

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

F3 · price: This transaction was executed in multiple trades at prices ranging from $46.20 to $46.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 5

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,525

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000745 · form4.xml · derivative · entry 8

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 12,176 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

F2 · price: This transaction was executed in multiple trades at prices ranging from $44.44 to $46.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,444

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000744 · form4.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 866,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $43.80 to $46.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000898432-21-000745 · form4.xml · derivative · entry 7

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,176

Underlying: Common Stock · 4,332 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

SEC source: 0000898432-21-000745 · form4.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,600

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000740 · form4.xml · derivative · entry 6

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,508

Underlying: Common Stock · 37,454 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

F3 · price: This transaction was executed in multiple trades at prices ranging from $42.25 to $44.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,722

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000740 · form4.xml · derivative · entry 5

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,962

Underlying: Common Stock · 6,038 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

F2 · price: This transaction was executed in multiple trades at prices ranging from $41.20 to $41.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-21-000740 · form4.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,306

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000739 · form4.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 876,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $39.53 to $41.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000898432-21-000738 · form4.xml · derivative · entry 3

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,715 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option was granted on 12-15-2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000738 · form4.xml · nonDerivative · entry 2

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,595

F1 · price: This transaction was executed in multiple trades at prices ranging from $40.58 to $41.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and priced at which the transaction was effected.

SEC source: 0000898432-21-000738 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,310

SEC source: 0000898432-21-000730 · form4.xml · derivative · entry 9

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,715

Underlying: Common Stock · 2,003 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on 12-15-2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 6

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,595

F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and priced at which the transaction was effected.

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 5

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,598

SEC source: 0000898432-21-000730 · form4.xml · derivative · entry 8

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,718

Underlying: Common Stock · 4,255 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on 12-15-2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 4

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,595

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 3

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,850

SEC source: 0000898432-21-000730 · form4.xml · derivative · entry 7

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,973

Underlying: Common Stock · 2,027 shares

Expires 2024-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option was granted on 12-15-2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 2

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,595

F1 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $41.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and priced at which the transaction was effected.

SEC source: 0000898432-21-000730 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · COO, CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,622

SEC source: 0000898432-21-000723 · form4.xml · derivative · entry 9

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 1,234 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 6

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

SEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 5

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,502

F1 · price: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000723 · form4.xml · derivative · entry 8

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,234

Underlying: Common Stock · 9,479 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

SEC source: 0000898432-21-000723 · form4.xml · nonDerivative · entry 4

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,268

F3 · price: This transaction was executed in multiple trades at prices ranging from $38.60 to $39.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.